NYSE:NVO
Novo-Nordisk (NVO)
Financials 
Technical Analysis 
Aug 8, 2026, 12:00 amThis summary was created by AI, based on 32 opinions in the last 12 months.
Novo Nordisk (NVO) is facing significant competition in the GLP-1 drug market, primarily from Eli Lilly (LLY), which has emerged as a leader due to its aggressive marketing and advancements in research and development. Many experts suggest that while NVO has a historically strong franchise, particularly with its weight-loss drug, its current stock performance is under pressure and not projected to see substantial earnings growth in the near term. Some analysts consider NVO to be a value trap, pointing to the challenges it faces, including management changes and increasing competition, particularly from generics. Despite this, there are opinions that highlight the long-term potential of NVO, especially with regards to the growing obesity and metabolic health markets. However, short-term caution is advised, and many experts prefer LLY due to its better prospects and market positioning.
Does not own any stock in company, Has had impressive sales record with organic growth. Pressure on diabetes pricing in the USA. Expecting new products coming onto market to benefit the company. Large portion if US(40%) living with obesity. Expensive at current share price.
Darren Sissons
David Driscoll
David FingoldDavid Driscoll
Paul Harris, CFADavid DriscollDavid DriscollIt's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.
Paul Harris, CFADavid Driscoll'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Top supplier of insulin. A very good company. Their diabetes drug has sold out so shares have plateaued. That said, he prefers Eli Lilly.